Elo Mutual Pension Insurance Co Increases Holdings in Bristol-Myers Squibb (NYSE:BMY)
Elo Mutual Pension Insurance Co Increases Holdings in Bristol-Myers Squibb (NYSE:BMY)
Elo Mutual Pension Insurance Co boosted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 4.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 174,571 shares of the biopharmaceutical company's stock after purchasing an additional 8,030 shares during the period. Elo Mutual Pension Insurance Co's holdings in Bristol-Myers Squibb were worth $12,749,000 at the end of the most recent reporting period.
根据百时美施贵宝最近提交给美国证券交易委员会(美国证券交易委员会)的文件，ELO共同养老保险公司在第一季度将其持有的百时美施贵宝(纽约证券交易所代码：BMY-GET评级)的股票增持了4.8%。该公司持有这家生物制药公司174,571股股票，在此期间又购买了8,030股。在最近一次报告期结束时，ELO共同养老金保险公司在百时美施贵宝持有的股份价值12,749,000美元。
A number of other hedge funds also recently bought and sold shares of the business. Norges Bank bought a new stake in Bristol-Myers Squibb during the 4th quarter valued at approximately $1,413,962,000. California Public Employees Retirement System boosted its position in Bristol-Myers Squibb by 59.0% during the 1st quarter. California Public Employees Retirement System now owns 11,771,544 shares of the biopharmaceutical company's stock valued at $859,676,000 after acquiring an additional 4,367,193 shares in the last quarter. Primecap Management Co. CA boosted its position in Bristol-Myers Squibb by 16.9% during the 4th quarter. Primecap Management Co. CA now owns 22,114,455 shares of the biopharmaceutical company's stock valued at $1,378,836,000 after acquiring an additional 3,195,680 shares in the last quarter. Pzena Investment Management LLC boosted its position in Bristol-Myers Squibb by 213.7% during the 1st quarter. Pzena Investment Management LLC now owns 3,625,787 shares of the biopharmaceutical company's stock valued at $264,791,000 after acquiring an additional 2,470,079 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in Bristol-Myers Squibb by 17.0% during the 4th quarter. Deutsche Bank AG now owns 15,372,985 shares of the biopharmaceutical company's stock valued at $958,504,000 after acquiring an additional 2,232,347 shares in the last quarter. Hedge funds and other institutional investors own 73.07% of the company's stock.
其他一些对冲基金最近也买入和卖出了该公司的股票。挪威银行在第四季度购买了百时美施贵宝的新股份，价值约1,413,962,000美元。加州公共雇员退休制度在第一季度将其在百时美施贵宝的头寸增加了59.0%。加州公共雇员退休系统现在拥有11,771,544股这家生物制药公司的股票，价值859,676,000美元，在上个季度额外购买了4,367,193股。PrimeCap Management Co.CA在第四季度将其在百时美施贵宝(Bristol-Myers Squibb)的头寸增加了16.9%。PrimeCap Management Co.CA现在拥有这家生物制药公司22,114,455股股票，价值1,378,836,000美元，上个季度又购买了3,195,680股。Pzena Investment Management LLC在第一季度将其在百时美施贵宝的头寸提高了213.7%。Pzena Investment Management LLC现在拥有这家生物制药公司3,625,787股股票，价值264,791,000美元，上个季度又收购了2,470,079股。最后，德意志银行(Deutsche Bank AG)在第四季度将其在百时美施贵宝的头寸提高了17.0%。德意志银行(Deutsche Bank AG)目前持有这家生物制药公司15,372,985股股票，价值958,504,000美元，上个季度又收购了2,232,347股。对冲基金和其他机构投资者持有该公司73.07%的股票。
Bristol-Myers Squibb Stock Down 0.3 %
百时美施贵宝股价下跌0.3%
BMY stock traded down $0.26 during midday trading on Thursday, hitting $74.60. The company's stock had a trading volume of 221,056 shares, compared to its average volume of 9,103,090. The company has a market cap of $159.29 billion, a PE ratio of 24.87, a P/E/G ratio of 1.59 and a beta of 0.40. Bristol-Myers Squibb has a 12 month low of $53.22 and a 12 month high of $80.59. The company has a current ratio of 1.44, a quick ratio of 1.34 and a debt-to-equity ratio of 1.14. The firm's 50-day moving average is $74.94 and its 200-day moving average is $72.99.
周四午盘，BMY股价下跌0.26美元，触及74.60美元。该公司股票的成交量为221,056股，而其平均成交量为9,103,090股。该公司市值为1,592.9亿美元，市盈率为24.87倍，市盈率为1.59倍，贝塔系数为0.40。百时美施贵宝的12个月低点为53.22美元，12个月高位为80.59美元。该公司的流动比率为1.44，速动比率为1.34，债务权益比率为1.14。该公司的50日移动均线切入位在74.94美元，200日移动均线切入位在72.99美元。
Bristol-Myers Squibb Announces Dividend
百时美施贵宝宣布分红
The business also recently announced a quarterly dividend, which was paid on Monday, August 1st. Shareholders of record on Friday, July 1st were paid a dividend of $0.54 per share. The ex-dividend date of this dividend was Thursday, June 30th. This represents a $2.16 dividend on an annualized basis and a yield of 2.90%. Bristol-Myers Squibb's dividend payout ratio is presently 71.76%.
该公司最近还宣布了季度股息，股息于8月1日(星期一)支付。7月1日(星期五)登记在册的股东获得了每股0.54美元的股息。本次股息除息日期为6月30日星期四。这意味着年化股息为2.16美元，收益率为2.90%。百时美施贵宝目前的股息支付率为71.76%。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Several analysts have weighed in on BMY shares. Guggenheim lifted their price objective on Bristol-Myers Squibb from $72.00 to $80.00 in a research report on Monday, May 2nd. Raymond James cut Bristol-Myers Squibb from an "outperform" rating to a "market perform" rating in a research report on Friday, June 3rd. They noted that the move was a valuation call. UBS Group boosted their price target on Bristol-Myers Squibb to $73.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 27th. Truist Financial boosted their price target on Bristol-Myers Squibb from $76.00 to $81.00 in a research report on Monday, May 2nd. Finally, JPMorgan Chase & Co. boosted their price target on Bristol-Myers Squibb from $80.00 to $85.00 in a research report on Thursday, July 28th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of "Moderate Buy" and a consensus target price of $75.57.
几位分析师对BMY的股票进行了分析。在5月2日周一的一份研究报告中，古根海姆将百时美施贵宝的目标价从72.00美元上调至80.00美元。雷蒙德·詹姆斯在6月3日星期五的一份研究报告中将百时美施贵宝的评级从“跑赢大盘”下调至“市场表现”。他们指出，此举是一次估值预测。瑞银集团在7月27日周三的一份研究报告中将百时美施贵宝的目标价上调至73.00美元，并给予该股“跑赢大盘”的评级。在5月2日星期一的一份研究报告中，Truist Financial将百时美施贵宝的目标价从76.00美元上调至81.00美元。最后，摩根大通在7月28日星期四的一份研究报告中将百时美施贵宝的目标价从80.00美元上调至85.00美元。一名分析师对该股的评级为卖出，四名分析师给予持有评级，七名分析师给予买入评级，一名分析师给予该股强烈买入评级。根据MarketBeat.com的数据，百时美施贵宝目前的共识评级为“中等买入”，共识目标价为75.57美元。
Insider Buying and Selling at Bristol-Myers Squibb
百时美施贵宝的内幕买卖
In other Bristol-Myers Squibb news, EVP Sandra Leung sold 65,000 shares of the business's stock in a transaction on Monday, June 6th. The shares were sold at an average price of $74.89, for a total transaction of $4,867,850.00. Following the completion of the sale, the executive vice president now directly owns 308,627 shares in the company, valued at approximately $23,113,076.03. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO Giovanni Caforio sold 30,000 shares of the company's stock in a transaction on Monday, June 13th. The stock was sold at an average price of $74.04, for a total value of $2,221,200.00. Following the completion of the sale, the chief executive officer now directly owns 551,104 shares in the company, valued at approximately $40,803,740.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sandra Leung sold 65,000 shares of the company's stock in a transaction on Monday, June 6th. The stock was sold at an average price of $74.89, for a total value of $4,867,850.00. Following the completion of the sale, the executive vice president now owns 308,627 shares of the company's stock, valued at $23,113,076.03. The disclosure for this sale can be found here. Company insiders own 0.09% of the company's stock.
在百时美施贵宝的其他新闻中，执行副总裁桑德拉·梁在6月6日星期一的一笔交易中出售了该公司6.5万股股票。这些股票的平均价格为74.89美元，总成交金额为4,867,850.00美元。出售完成后，执行副总裁总裁现在直接持有该公司308,627股股份，价值约23,113,076.03美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过这个链接获得。在其他新闻方面，首席执行官乔瓦尼·卡福里奥在6月13日星期一的一次交易中出售了30,000股公司股票。这只股票的平均售价为74.04美元，总价值为2221,200.00美元。出售完成后，首席执行官现在直接拥有公司551,104股，价值约40,803,740.16美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，这份文件可以在美国证券交易委员会的网站上找到。此外，执行副总裁梁淑仪在6月6日星期一的一笔交易中出售了6.5万股该公司的股票。这只股票的平均售价为74.89美元，总价值为4867,850.00美元。出售完成后，执行副总裁总裁现在持有该公司308,627股股票，价值23,113,076.03美元。此次拍卖的披露信息可在此处找到。公司内部人士持有该公司0.09%的股份。
Bristol-Myers Squibb Company Profile
百时美施贵宝公司简介
(Get Rating)
(获取评级)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
百时美施贵宝公司在全球发现、开发、许可、制造和营销生物制药产品。它提供血液学、肿瘤学、心血管学、免疫学、纤维化、神经科学和新冠肺炎疾病的产品。该公司的产品包括治疗多发性骨髓瘤的口服免疫调节药物Revlimid；用于降低NVAF中风/系统性栓塞风险和治疗DVT/PE的口服抑制剂Eiquis；用于抗癌适应症的Opdivo；用于多发性骨髓瘤患者的Pomalyst/Imnovid；以及用于成人活动期RA和牛皮癣关节炎的Orencia。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
- 3 Stable Growth Stocks for Bumpy Times
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- 免费获取StockNews.com关于百时美施贵宝(BMY)的研究报告
- 找到并获利于52周低点的股票交易
- 迪士尼(NYSE：DIS)的股票刚刚给了投资者一个巨大的信号
- 清洁能源法案通过后，太阳能股大放异彩
- 颠簸时代的3只稳定成长股
- 大型和小型石油和天然气类股盈利后反弹
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
接受百时美施贵宝日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对百时美施贵宝及相关公司评级的每日摘要。
译文内容由第三方软件翻译。